COGT Cogent Biosciences, Inc. Insider Trading

Fairmount Funds Management LLC (Director) sells 7,000,000 shares of COGT at $34.66; retains 5,503,418 shares post-sale.

Fairmount Funds Management LLC executed a substantial sale of 7,000,000 shares (7.00M shares) on 2026-03-31 at $34.66, reducing holdings by -56.0% to 5,503,418 shares (5.50M shares). The filer's cross-ticker track record shows only 2 prior sells with an average 30-day return of -3.9%, offering limited historical context; same-ticker history is more recent, with a prior sell on 2026-01-22 that posted a +2.6% 30-day return. Current price of $38.49 sits 8.6% below the 52-week high of $42.11, and the stock declined -0.9% over 30 days. COGT remains deeply unprofitable (net income of $-80.9M in the latest full year) with severely contracted revenue (-65.0% annual growth) and minimal recent quarterly revenue of $312.0K, creating a fundamental backdrop of significant operational distress that contextualizes the director's partial position reduction.

Fairmount Funds Management LLC sold 3,500,000 shares of COGT at $36.40; stock now $39.53 after 90d +161.3% surge.

Fairmount Funds Management LLC, a director, sold 3,500,000 shares (3.50M shares) at $36.40 on 2026-01-22, reducing its stake by -38.9% from 9,003,418 to 5,503,418 shares (5.50M shares), for total proceeds of $127,400,000.00 ($127.4M). The sale occurred during a period of extraordinary momentum: COGT appreciated +161.3% over the prior 90 days and is currently trading at $39.53, -6.1% from its 52-week high of $42.11. This timing is particularly noteworthy given Fairmount's prior activity at COGT: the director purchased shares on 2025-07-10 and realized +73.1% returns over the subsequent 90 days, demonstrating successful entry execution. However, the fundamental backdrop warrants attention—the company posted Revenue of $312,000.00 ($312.0K) in its latest quarter, a -65.0% annual decline, and remains significantly unprofitable with a Net income of $-80,930,000.00 ($-80.9M). The sale exits a major position shortly after substantial equity appreciation but leaves Fairmount with 5,503,418 shares (5.50M shares) of equity remaining, indicating continued exposure to a company with severe revenue contraction and persistent losses.

CMO Jessica Sachs sold 82,642 COGT shares at $38.70 on 2025-12-26 for $3.2M; now holds 133,938 shares post-sale.

Jessica Sachs, Chief Medical Officer, executed a substantial sale of 82,642 shares (reducing her holdings by -38.2% from 216,580 to 133,938 shares) at $38.70 per share. The sale occurred near the company's 52-week high of $42.11 and approximately 4% above current price of $37.12. This large reduction in insider equity stake coincides with severe operational challenges: Cogent reported only $312,000 in latest quarterly revenue against a net loss of $-80,930,000, with annual revenue growth declining -65.0% year-over-year and full-year profitability remaining deeply negative. The CMO's substantial divestment represents a material reduction in personal exposure to a company facing sharply declining revenues and significant operating losses.

CFO John L. Green sold 77,000 shares (36.9% of holdings) at $38.68, reducing stake to 131.8K shares amid -65% annual revenue decline

Green sold 77,000 shares at $38.68 on 2025-12-26 for $2,978,360, reducing his holdings by 36.9% from 208.8K to 131.8K shares. This sale occurred as COGT faces significant operational headwinds: annual revenue contracted by 65.0% to $312,000 in the latest quarter, while full-year net income was negative at $-80,930,000. The stock is trading at $37.12, down 11.8% from its 52-week high of $42.11, where the CFO's sale price of $38.68 sits near the upper range, though recent 30-day performance shows -7.7% weakness. The combination of substantial revenue decline, persistent unprofitability, and the CFO's material reduction in personal exposure warrants investor review of the company's operational trajectory and cash position.

Chief Legal Officer Evan Kearns sells 65,000 shares (-37.3% of holdings) at $38.70 amid 90-day surge of +162.7%

Kearns' sale of 65,000 shares at $38.70 represents a substantial reduction in his position at a price significantly elevated relative to the company's 52-week range ($4.02–$42.11). The stock has surged +162.7% over the past 90 days before this transaction, placing the sale price near the upper end of recent trading—11.8% below the 52-week high of $42.11. Concurrent with this price strength, the company reported quarterly revenue of $312.0K with a net loss of $-80.9M and annual revenue decline of -65.0%, indicating deepening fundamental deterioration despite short-term equity appreciation. A senior executive's large discretionary sale at a multi-quarter peak, against a backdrop of worsening profitability and operational contraction, warrants investor scrutiny of whether recent market gains are sustainable.

Chief Scientific Officer Robinson sells 90,000 shares (39.1% reduction) at $38.74, trimming position to 140,002 shares amid -65.0% revenue decline and $-80.9M annual net loss

Robinson John Edward, Chief Scientific Officer, executed a substantial reduction in his equity position, divesting 90,000 shares at $38.74 (total value $3,486,600.00), leaving him with 140,002 shares post-transaction—a 39.1% reduction from 230,002 shares. This sale occurs against a backdrop of severe operational deterioration: the company reported $312,000 in latest-quarter revenue (a -65.0% annual revenue decline) and full-year net income of $-80,930,000, indicating the company is deeply unprofitable. The stock has declined 7.7% over the past 30 days and trades 11.8% below its 52-week high of $42.11. The magnitude and timing of this insider sale—coinciding with worsening financial results and persistent negative earnings—warrants scrutiny of whether the Chief Scientific Officer's conviction in the company's near-term prospects remains intact.

Director Fairmount Funds invested $24,999,993.00 in 2,777,777 COGT shares at $9.00; holdings surge 44.6% to 9,003,418 shares amid loss of -$72.0M and -65.0% revenue decline

Fairmount Funds Management LLC, a director holding, purchased 2,777,777 shares of Cogent Biosciences for $24,999,993.00 at $9.00, increasing its position by 44.6% to 9,003,418 shares. This substantial accumulation occurs in a company with severe financial distress: Cogent generated only $312,000 in latest-quarter revenue, reported a -$72.0M annual net loss, and suffered -65.0% year-over-year revenue contraction. The purchase price of $9.00 is 18.8% below the current price of $11.09, placing the transaction well inside the 52-week range of $4.02–$12.30. The director's cross-ticker track record shows a 36.36% 90-day win rate with -13.1% average 90-day return, indicating historically challenged execution; however, the 30-day momentum of +56.6% has favored the position since the transaction. The magnitude of this buy—material both in dollar value and as a percentage of existing holdings—deserves scrutiny given the company's unprofitable trajectory and severely depressed revenue base.

Chief Commercial Officer Cole Pinnow purchased 43,750 shares of COGT at $7.60; holdings rose +2085.3% to 45,848 shares amid -65.0% revenue decline and $-70.6M net loss

Pinnow's acquisition of 43,750 shares at $7.60 represents a substantial increase in personal equity stake, with post-transaction holdings of 45,848 shares representing a +2085.3% increase from the 2,098 shares held prior. The timing is notable given deteriorating company fundamentals: annual revenue contracted -65.0%, the company posted a net loss of $-70.6M in its most recent full fiscal year, and the latest quarterly revenue was only $312,000.00. The stock is currently -34.0% from its 52-week high of $12.30, whereas Pinnow's purchase at $7.60 occurred near the lower end of the 52-week range ($4.38–$12.30). The purchase signal and the scale of personal capital deployed warrant investor scrutiny of whether this reflects management's view of intrinsic value relative to current market pricing, set against the severe revenue contraction and ongoing losses.